

As part of our commitment to sharing quarterly updates, we want to provide you with important information about the supply of Norditropin® (somatotropin) injection 5mg, 10mg, 15mg, and 30mg and Sogroya® (somapacitan-beco) injection 5mg, 10mg, and 15mg.

We know the past year has been difficult for many patients and prescribers and, in some cases, there were interruptions to treatment because of ongoing supply issues. Please know that we have been working diligently and taking every action possible to restore full capacity across our portfolio and ensure that more patients can gain access to their treatment. For patients who are unable to fill their prescription, we recommend they speak with their healthcare provider to determine the best course of action.

Regarding Norditropin®, we are pleased to report that we have been able to provide the market with more consistent supply of the product. To ensure that we continue to improve and stabilize the Norditropin® supply for the remainder of 2024, we are prioritizing the production of the 10mg and 15mg pen strengths and are temporarily discontinuing the 30mg pens. This will result in an increase in overall availability of Norditropin®. The overall supply of Norditropin® 10mg and 15mg is expected to remain intact as the 10mg and 15mg strengths are both currently available and expected to be maintained as we continue to prioritize their production. We expect continued intermittent supply constraints of the 5mg pen strength through Q2 2024.

We are currently experiencing a short-term interruption of the 15mg pen strength of Sogroya®. However, both the Sogroya® 5mg and 10mg pen strengths are available and we have ample supply for new and existing patients during the short-term interruption of the 15mg pen strength of Sogroya® which is expected to return in May. These other pen sizes are available as a solution for those patients who would otherwise use the Sogroya® 15mg pen.

We acknowledge the impact these supply challenges will have on patients, their families, and healthcare professionals, and have been proactively taking these essential steps to resolve them. As a long-standing partner within this community, we remain steadfast in our commitment to serving patients and healthcare professionals, and providing patients with the treatments they rely on.

Sincerely,
Novo Nordisk

Norditropin® and Sogroya® are registered trademarks of Novo Nordisk Health Care AG.

Novo Nordisk is a registered trademark of Novo Nordisk A/S.

All other trademarks, registered or unregistered, are the property of their respective owners.

©2024 Novo Nordisk All rights reserved. US24REND00012 March 2024